EUCTR2005-000604-14-LV进行中（未招募）不适用
A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy - ASCEND
Speedel Pharma Ltd.0 个研究点目标入组 2,364 人开始时间: 2006年8月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,364
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients must be between 21 and 80 years of age, inclusive.
- •Patients with type 2 diabetes mellitus diagnosed for at least 3 years and receiving oral anti-diabetic treatment and/or insulin.
- •Female patients will either be: Post menopausal for greater than or equal to 2 years, Surgically sterile Or, if of childbearing potential, using double contraception, with at least one method being barrier contraception. Women of childbearing potential must have a negative pregnancy test at screening and at randomisation. Pregnancy tests will be repeated monthly during the study.
- •Proteinuria defined as ACR greater than or equal to 50mg/mmol.
- •Patients with serum creatinine between 1.5 and 3.2 mg/dL.
- •On standard treatment for diabetic nephropathy (such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or the combination thereof) for at least 6 months before study start. Patients who are intolerant to ACE inhibitors or ARBs will be allowed to enter the study.
- •Able to provide written informed consent prior to study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with type 1 diabetes mellitus.
- •Patients with proteinuria of non-diabetic origin.
- •Patients with a renal transplant.
- •Patients who have undergone nephrectomy
- •Patients with an estimated GFR = 15 mL/min
- •Patients with blood pressure greater than or equal to 160/100 mmHg with or without antihypertensive medication.
- •Patients with glycosylated haemoglobin (HbA1c) > 12 %.
- •Patients with normal sinus rhythm who do not have a pacemaker, are not taking anti-arrhythmic drugs and do not have complete bundle branch block, but who have absolute QT or QTc greater than 500 msec
- •Patients with recent (60 days) percutaneous transluminal coronary angioplasty (PTCA), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or any other major surgical intervention.
- •Patients with recent (60 days) acute myocardial infarction, unstable angina, stroke or transient ischaemic attack.
- •Patients with CHF New York Heart Association grade III or IV
- •Patients with life-threatening arrhythmias including those at high risk for QT/QTc prolongation such as a family history of Long QT Syndrome, severe hypokalaemia, etc
- •Patients who are positive for hepatitis B surface antigen or hepatitis C antibody at Visit 1 (Screening) and who have abnormal liver function (specifically ALAT/ASAT greater than 1 x ULN)
- •Patients who have been treated with an endothelin receptor antagonist in the 3 months prior to screening.
- •Patients being treated with spironolactone or eplerenone at entry into the study
- •Patients treated with amiodarone in the 4 weeks prior to entry into the study.
- •Women of child-bearing potential not using adequate contraception as specified in the inclusion criteria given above.
- •Pregnant or lactating women.
- •Patients with a neoplasm who are deemed to live < 12 months.
- •Patients with history of alcohol and/or drug abuse.
- •Patients with a known history of a major psychiatric condition that would interfere with the conduct of the trial.
- •Patients with active endocarditis and/or pericarditis.
- •Patients allergic to avosentan or any other endothelin receptor antagonist.
- •Patients who participated in another clinical study or who have donated blood within 60 days of being randomised to this study.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPDChronic obstructive pulmonary disease (COPD)MedDRA version: 18.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-004715-37-DEAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden250
进行中（未招募）
不适用
Safety and efficacy of empagliflozin in two different daily doses as add-on to metformin therapy in patients with type 2 diabetes mellitusType 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2012-000905-53-ITBOEHRINGER ING.1,900
进行中（未招募）
1 期
A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPDChronic obstructive pulmonary disease (COPD)MedDRA version: 17.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-004715-37-GBAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden269
进行中（未招募）
1 期
GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes.Type 2 diabetesMedDRA version: 17.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-001140-61-GBGW Research Ltd.200
进行中（未招募）
不适用
A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy - ASCENDDiabetic NephropathyEUCTR2005-000604-14-FISpeedel Pharma Ltd.2,364